Cyclopharm Limited

CYC

AU000000CYC5

Advanced Medical Equipment & Technology

Market Closed - Australian S.E. Other stock markets 04:11:05 13/02/26 pm AEDT			5-day change	1st Jan Change
0.8300 ^AUD	-8.79%		-15.74%	-15.31%

04/02	Cyclopharm Raises AU$14 Million via Placement; Shares Fall 17%	MT
04/02	Cyclopharm to raise A$14 million (before costs) at A$0.95 per share	RE

Cyclopharm to raise A$14 million (before costs) at A$0.95 per share

Published on 02/04/2026 at 12:20 pm AEDT

Reuters

Latest news about Cyclopharm Limited

04/02	Cyclopharm Raises AU$14 Million via Placement; Shares Fall 17%	MT
04/02	Cyclopharm to raise A$14 million (before costs) at A$0.95 per share	RE
02/02	Cyclopharm logs FY unaudited operating revenue A$32.3 mln	RE
02/02	Cyclopharm seeks trading halt	RE
29/01	Cyclopharm Enters Research Collaboration With Macquarie University To Evaluate Treatment For Chronic Obstructive Pulmonary Disease	MT
27/01	Australian Shares Rise; Fortescue Secures Shareholder Approval to Fully Acquire Alta Copper	MT
27/01	Cyclopharm's Lung Imaging Product Recognized as Preferred Agent in Draft Clinical Guideline; Shares Up 13%	MT
27/01	Cyclopharm Says Insurer Assumes Conduct of Defense Against 4DMedical Lawsuit In Victoria Supreme Court, Shares Jump 11%	MT
27/01	Cyclopharm confirms insurer accepted indemnity in respect of proceedings	RE
12/01	Cyclopharm Agrees to Implement Lung Imaging Technology at US-Based Children's Hospital	MT
22/12	Cyclopharm Says Technegas Technology Approved in Colombia; Shares Up 5%	MT
21/11	Cyclopharm Partners With Western University to Test Technegas in Mild Asthma	MT
12/11	Cyclopharm Finalizes Sale of Cyclotron Asset	MT
12/11	Cyclotek Pty Ltd completed the acquisition of Non-core Cyclotron asset of Cyclopharm Limited.	CI
08/10/25	Shares of Cyclopharm Fall on Legal Action by 4DMedical	MT

Cyclopharm Limited is an Australia-based radiopharmaceutical company. The Company's principal activity is engaged in the manufacture and sale of medical equipment and radiopharmaceuticals, including associated research and development and distribution of third-party products to the diagnostic imaging sector. Its segments include Technegas and Molecular Imaging. The Technegas segment is a supplier of diagnostic equipment and consumables used by physicians in the detection of pulmonary embolism and a distributor of products to the diagnostic imaging sector. The Molecular Imaging segment produces radiopharmaceuticals to be used by physicians in the detection of cancer, neurological disorders and cardiac disease. The Company uses Technegas technology, which is a structured ultra-fine dispersion of radioactive labelled carbon, produced by using driedTechnetium-99m in a carbon crucible. The Company distributes its products in approximately 65 countries.

Employees

Sector

Advanced Medical Equipment & Technology

Calendar

25/02 - Q4 2025 Earnings Release (Projected)

More about the company